June 27, 2020 / 4:35 AM / 13 days ago

BRIEF-Carlyle And Piramal Pharma Sign Agreement On A 20% Strategic Growth Investment

June 27 (Reuters) - Carlyle Group Inc:

* THE CARLYLE GROUP LP - CARLYLE AND PIRAMAL PHARMA SIGN AGREEMENT ON A 20% STRATEGIC GROWTH INVESTMENT

* INTEGRATE PIRAMAL ENTERPRISES’ PHARMA BUSINESSES INTO ITS SUBSIDIARY PIRAMAL PHARMA LIMITED

* CARLYLE-TRANSACTION VALUES PHARMA BUSINESS AT ENTERPRISE VALUE US$2,775 MILLION WITH UPSIDE COMPONENT OF UP TO US$360 MILLION DEPENDING ON CO’S FY21 PERFORMANCE

* CARLYLE GROUP - ESTIMATED EQUITY CAPITAL INVESTMENT FOR CARLYLE’S 20% STAKE IN PIRAMAL PHARMA WOULD AMOUNT TO US$490 MILLION

* CARLYLE GROUP - CAPITAL RAISE TO ACCELERATE PIRAMAL PHARMA’S ORGANIC AND INORGANIC GROWTH PLANS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below